Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
about
Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of CardiologyVascular endothelial dysfunction and pharmacological treatmentSpatial control of cAMP signalling in health and diseaseHeart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesGenetic Regulation of Endothelial Vasomotor FunctionDigital ulcers in systemic sclerosisPDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cellsType 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.Sub-Nanomolar Sensitivity of Nitric Oxide Mediated Regulation of cGMP and Vasomotor Reactivity in Vascular Smooth Muscle.Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.The right ventricle: biologic insights and response to diseaseEffects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy.Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibitionCardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibitionDifferential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.Drug repositioning using in silico compound profiling.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension.Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells.Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arteriolesDNA microarray and signal transduction analysis in pulmonary artery smooth muscle cells from heritable and idiopathic pulmonary arterial hypertension subjectsPhosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory CytokinesAdenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarctionSickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia.A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil.Phosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsThe right ventricle: biologic insights and response to disease: updated.Targeting phosphodiesterases in anti-platelet therapySarcolemma-localized nNOS is required to maintain activity after mild exerciseExpression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.
P2860
Q26765793-F5EDF7BB-3B5F-4596-81C1-934DC9EA064FQ26774561-5EB0A041-173A-4D39-A807-5D966C8AA7D3Q26866056-F04E660D-3DD5-44E4-8F02-7F1B504A6B4AQ27000263-5CDDADB5-CCDD-4803-986B-0FBFD5155FC4Q28073934-DF855113-69B3-42C0-831B-4C7E4B378163Q28080196-537B8C84-CA98-45D6-AADA-ACB65BD9078BQ28262626-73E9F819-653B-442E-B8BA-B68D810734CCQ30486054-ECB68724-76F3-498F-A48C-0161CFF43507Q30519970-7AD4EDE8-3EEE-44AA-8F9E-24B6379A59A2Q30548444-26E1CE0A-C763-4591-9766-048A5BAEBA13Q33552229-EC07ABE4-0169-4035-B7D2-7E9E1D6C1EB6Q33578032-ECF90682-4D56-4522-89B0-0CC2D7BD07C5Q33686622-84316FFC-60AC-4E45-ABE2-155B00FC404EQ33724430-3513A474-C625-415C-95F6-DC684846E53BQ33777629-87A49E00-E01A-4130-8A01-F6247B13E0AAQ33799926-1B42CC26-8A14-4825-B128-C0AF1A85746DQ33916555-B1B9B616-0B54-4342-9BB2-6630C69DC4CAQ33966155-1098DF80-2293-4F77-B3D1-1B777392ABD4Q34023606-E6A52CB8-BF73-4EB8-B4AB-87D866ABEB08Q34150566-DBFAEEAC-D9C4-4EF9-8976-D7AE61130A12Q34172485-23DF9A98-3552-4073-9022-4898EE5A75F3Q34244951-0A685ACD-B539-44CD-B9F8-39647623CE1EQ34252901-4C4B4C3A-E585-456B-ABD1-B1B065B24493Q34295259-8F720A11-8315-4704-B643-96B007881497Q34300912-9543F7ED-4C86-4690-BCD5-A0BEA87EA660Q34357737-88AB5846-7E6A-444E-8E3D-65A0EDABB229Q35141990-7DFCFC7E-078C-4C16-B570-A7359E2F5D99Q35346456-2D3D00E1-2A10-43FE-83B3-9B2C1500033AQ35740400-4F008593-1FE7-4161-817D-905FFF285803Q35879351-5FF1C29F-2F66-48A6-A437-C7780F1CBC35Q35994136-2BF19719-2E9A-419D-ACB5-52CFEDF66122Q36056143-7CE4751A-6701-44A9-AC19-20897F9D1981Q36414291-5DBAA64A-BD34-4A34-825E-9EC3AC77C7A5Q36460566-0C408A53-7A86-460F-8A48-7C8015759D3EQ36644859-8CDB343B-6B0F-400F-9A10-B84A0EE62136Q36929627-6BFD4EF0-DA0B-48B6-844B-BFA71991A9C5Q36987100-BDBB9742-F50E-4F3E-A395-C934033DF6FAQ37012737-17A08D42-020B-4885-949A-B13E9D4F1848Q37245076-86C6869D-EE91-4E41-A765-75C967FF9E56Q37245123-D4A091E9-3854-41E0-B395-382C59D60057
P2860
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@en
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@nl
type
label
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@en
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@nl
prefLabel
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@en
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@nl
P2093
P1433
P1476
Phosphodiesterase type 5: expanding roles in cardiovascular regulation.
@en
P2093
David A Kass
Hunter C Champion
Joseph A Beavo
P304
P356
10.1161/CIRCRESAHA.107.162511
P577
2007-11-01T00:00:00Z